Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,398.00
Bid: 12,398.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 12,432.00
High: 12,482.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Spain probes patient death after taking AstraZeneca jab

Wed, 17th Mar 2021 20:09

(Alliance News) - Three cases of people who suffered from thrombosis after receiving the AstraZeneca PLC vaccine, one of whom died, are under investigation, Spanish health officials said Wednesday.

The announcement by Madrid's AEMPS medicines agency came two days after the government suspended use of the vaccine for at least a fortnight as a precaution.

The three cases happened between late Monday and early Tuesday. 

"It could be related to the vaccine or not," Health Minister Carolina Darias told a news conference.

"What we know so far is that in these three cases there is a temporal link but it has not been established that there is a causal link."

While she said she "understood the concerns", the minister stressed Spain has so far recorded just three cases of thrombosis out of the 975,661 people who received the AstraZeneca vaccine.

Press reports said  the person who died was a 43-year-old maths teacher in the southern city of Marbella with no pre-existing health conditions.

She suffered a cerebral haemorrhage and had complained of headaches after having the jab, but doctors attributed it to the normal side effects associated with the vaccine, Diario Sur newspaper reported.

Monday's decision to suspend all AstraZeneca shots came just hours after Germany, France and Italy announced similar moves linked to fears the vaccine could generate serious side effects such as blood clots which can cause swellings, heart attacks and haemorrhages. 

In a statement, the AEMPS said the three cases might be linked to the "formation of blood clots in areas of the body where they are less common" without drawing firm conclusions.

Investigators were "gathering more information and carrying out an exhaustive investigation".

Spain, which is also administering the Pfizer Inc/BioNtech SE and Moderna Inc vaccines, has so far recorded more than 72,500 coronavirus deaths from more than 3.2 million cases.

World Health Organization experts on Wednesday recommended countries continue to use the AstraZeneca vaccine.

That echoed a similar statement from the European Medicines Agency saying there was no link with clots.

The EMA is holding an extraordinary meeting Thursday to finalise conclusions on the blood clot issue and "make any necessary recommendations for further action".

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.